Implementation of radiation segmentectomy for early-stage hepatocellular carcinoma
- PMID: 35617979
- DOI: 10.1016/S2468-1253(22)00161-3
Implementation of radiation segmentectomy for early-stage hepatocellular carcinoma
Conflict of interest statement
RJL has received consulting fees from Boston Scientific, Bard, Varian, ABK Medical, Alhambra Medical, and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Boston Scientific; an NIH grant, paid to his institution (NIH R01 CA 233787); and membership of the Executive Council Society of Interventional Radiology. RS has received consulting fees from Boston Scientific, Sirtex, Cook, Bard, Eisai, Genentech, and AstraZeneca.
Comment on
-
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study.Lancet Gastroenterol Hepatol. 2022 Sep;7(9):843-850. doi: 10.1016/S2468-1253(22)00091-7. Epub 2022 May 23. Lancet Gastroenterol Hepatol. 2022. PMID: 35617978 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical